Valproic acid reprograms the metabolic aberration of cisplatin treatment via ALDH modulation in triple-negative breast cancer cells

Valproic acid reprograms the metabolic aberration of cisplatin treatment via ALDH modulation in triple-negative breast cancer cells

We recently demonstrated that the histone deacetylase inhibitor valproic acid (VPA) reprograms the cisplatin-induced metabolome of triple-negative breast cancer (TNBC) cells, including a shift in hexose levels. Accordingly, here, we tested the hypothesis that VPA alters glucose metabolism in correla...

Full description

Bibliographic Details
Main Authors: Avital Granit Mizrahi, Ahinoam Gugenheim, Haneen Hamad, Roa’a Hamed, Nino Tetro, Ofra Maimon, Salome Khutsurauli, Hovav Nechushtan, Benjamin Nisman, Deborah Duran, Widad Samman, Liron Birimberg-Schwartz, Myriam Grunewald, Sara Eyal, Tamar Peretz
Format: Article
Language:English
Published: Frontiers Media S.A. 2023-10-01
Series:Frontiers in Cell and Developmental Biology
Subjects:
valproic acid
cisplatin
disulfiram
glucose
metabolism
aldehyde dehydrogenase
Online Access:https://www.frontiersin.org/articles/10.3389/fcell.2023.1217149/full

Internet

https://www.frontiersin.org/articles/10.3389/fcell.2023.1217149/full

Similar Items